The promises and challenges of patient-derived tumor organoids in drug development and precision oncology.
drug testing
patient derived tumor organoids
precision oncology
tumor models
Journal
Animal models and experimental medicine
ISSN: 2576-2095
Titre abrégé: Animal Model Exp Med
Pays: United States
ID NLM: 101726292
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
22
04
2019
revised:
25
07
2019
accepted:
27
07
2019
entrez:
28
11
2019
pubmed:
28
11
2019
medline:
28
11
2019
Statut:
epublish
Résumé
In the era of precision medicine, cancer researchers and oncologists are eagerly searching for more realistic, cost effective, and timely tumor models to aid drug development and precision oncology. Tumor models that can faithfully recapitulate the histological and molecular characteristics of various human tumors will be extremely valuable in increasing the successful rate of oncology drug development and discovering the most efficacious treatment regimen for cancer patients. Two-dimensional (2D) cultured cancer cell lines, genetically engineered mouse tumor (GEMT) models, and patient-derived tumor xenograft (PDTX) models have been widely used to investigate the biology of various types of cancers and test the efficacy of oncology drug candidates. However, due to either the failure to faithfully recapitulate the complexity of patient tumors in the case of 2D cultured cancer cells, or high cost and untimely for drug screening and testing in the case of GEMT and PDTX, new tumor models are urgently needed. The recently developed patient-derived tumor organoids (PDTO) offer great potentials in uncovering novel biology of cancer development, accelerating the discovery of oncology drugs, and individualizing the treatment of cancers. In this review, we will summarize the recent progress in utilizing PDTO for oncology drug discovery. In addition, we will discuss the potentials and limitations of the current PDTO tumor models.
Identifiants
pubmed: 31773090
doi: 10.1002/ame2.12077
pii: AME212077
pmc: PMC6762043
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
150-161Informations de copyright
© 2019 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.
Déclaration de conflit d'intérêts
None.
Références
Ann Surg Oncol. 2019 Jan;26(1):139-147
pubmed: 30414038
J Cell Physiol. 2017 Oct;232(10):2679-2697
pubmed: 27791270
Cancer Discov. 2018 Sep;8(9):1112-1129
pubmed: 29853643
Nat Rev Genet. 2018 Nov;19(11):671-687
pubmed: 30228295
Science. 2017 Jan 20;355(6322):
pubmed: 28104841
EMBO Mol Med. 2017 Feb;9(2):137-153
pubmed: 28028012
Nat Med. 2017 Dec;23(12):1424-1435
pubmed: 29131160
Cell. 2014 Sep 25;159(1):176-187
pubmed: 25201530
Stem Cell Res. 2018 Mar;27:109-120
pubmed: 29414601
Cell. 2018 Apr 5;173(2):515-528.e17
pubmed: 29625057
Animal Model Exp Med. 2019 Aug 13;2(3):150-161
pubmed: 31773090
Invest New Drugs. 2011 Dec;29(6):1475-81
pubmed: 20574790
Nature. 2009 May 14;459(7244):262-5
pubmed: 19329995
Respir Care. 2009 May;54(5):595-605
pubmed: 19393104
J Exp Med. 1953 May;97(5):695-710
pubmed: 13052828
Cancer Cell. 2004 Aug;6(2):111-6
pubmed: 15324694
Clin Transl Oncol. 2010 Jul;12(7):473-80
pubmed: 20615824
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Nat Commun. 2018 Jul 30;9(1):2983
pubmed: 30061675
Nat Rev Cancer. 2015 Nov;15(11):653-67
pubmed: 26493646
Proc Natl Acad Sci U S A. 1987 Jan;84(1):136-40
pubmed: 3467345
South Med J. 1993 Jan;86(1):38-41
pubmed: 8420014
Cancer Causes Control. 2010 Nov;21(11):1851-6
pubmed: 20628804
Nat Med. 2013 Jul;19(7):939-45
pubmed: 23727931
Ann Surg Oncol. 2018 Sep;25(9):2767-2775
pubmed: 30003451
Cell Rep. 2018 Jul 31;24(5):1363-1376
pubmed: 30067989
Development. 2015 Sep 15;142(18):3113-25
pubmed: 26395140
J Cell Biol. 2017 Jan 2;216(1):31-40
pubmed: 28031422
Int J Gynecol Cancer. 2017 Oct;27(8):1701-1707
pubmed: 28683005
Breast Cancer Res. 2012 Jan 16;14(1):R11
pubmed: 22247967
Mol Cells. 2016 Feb;39(2):77-86
pubmed: 26831452
Cancer Res Treat. 2018 Jan;50(1):1-10
pubmed: 28903551
Cell. 2018 Jan 11;172(1-2):373-386.e10
pubmed: 29224780
Eur J Cancer Prev. 2008 Nov;17(6):525-34
pubmed: 18941374
Sci Rep. 2018 Feb 13;8(1):2886
pubmed: 29440675
Biochim Biophys Acta. 2009 Apr;1795(2):92-103
pubmed: 19167460
Animal Model Exp Med. 2018 Jul 28;1(2):134-142
pubmed: 30891558
Dis Model Mech. 2008 Sep-Oct;1(2-3):78-82
pubmed: 19048064
Sci Rep. 2017 Oct 9;7(1):12870
pubmed: 28993684
Nat Med. 2015 Nov;21(11):1364-71
pubmed: 26501191
Science. 2018 Feb 23;359(6378):920-926
pubmed: 29472484